ClinicalTrials.gov
ClinicalTrials.gov Menu

Ultra Low Dose Radiation for Local Treatment of Cutaneous Mycosis Fungoides

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03398161
Recruitment Status : Recruiting
First Posted : January 12, 2018
Last Update Posted : August 14, 2018
Sponsor:
Information provided by (Responsible Party):
M.D. Anderson Cancer Center

January 8, 2018
January 12, 2018
August 14, 2018
January 6, 2018
September 2020   (Final data collection date for primary outcome measure)
Local Control in Management of Cutaneous Mycosis Fungoides (MF) with Low Dose Radiation [ Time Frame: 12 weeks after radiation therapy ]
Local control defined as complete response (CR) or partial response (PR) of the treated lesion.
Same as current
Complete list of historical versions of study NCT03398161 on ClinicalTrials.gov Archive Site
  • Overall Survival in Management of Cutaneous Mycosis Fungoides (MF) with Low Dose Radiation [ Time Frame: up to 2 years after radiation therapy ]
    Overall survival defined as the time from initiation of treatment until death; patients who are alive will be censored at the point of the last follow up visit.
  • Progression Free Survival (PFS) in Management of Cutaneous Mycosis Fungoides (MF) with Low Dose Radiation [ Time Frame: up to 2 years after radiation therapy ]
    Progression free survival (PFS) defined as the time from treatment until progression or death; patients who are alive and without progression of disease will be censored at the last followup timepoint or at 2 years whichever is latest.
  • Quality of Life in Management of Cutaneous Mycosis Fungoides (MF) with Low Dose Radiation [ Time Frame: Baseline, 4-6 weeks after radiation, 1-14 weeks after radiation, 6-8 months after radiation, then every 6-12 months after radiation for 2 years. ]
    Quality of life data obtained from the Skindex-16 survey summarized by domains.
Same as current
Not Provided
Not Provided
 
Ultra Low Dose Radiation for Local Treatment of Cutaneous Mycosis Fungoides
Ultra Low Dose Radiation for Local Treatment of Cutaneous Mycosis Fungoides

The goal of this clinical research study is to learn if low dose radiation therapy can help to control cutaneous mycosis fungoides.

Researchers would like to learn the level of effectiveness of this lower dose of radiation therapy because it is likely to have fewer side effects than the standard, higher dose.

This is an investigational study. It is investigational to treat cutaneous mycosis fungoides with lower doses of radiation than the standard, higher dose.

The study doctor can describe how the radiation therapy is designed to work.

Up to 50 participants will be enrolled in this study. All will be enrolled at MD Anderson.

Radiation Treatment:

Radiation will be applied directly to the lesion on the skin. A lower energy form of radiation will be used that mostly affects only the first inch of skin. The doctor will use a marker to mark the area of the skin that needs to be treated. The radiation team will then perform a calculation that determines how long your treatment will last to deliver the right dose of radiation. The radiation will then be delivered by a certified radiation therapist using a radiation treatment machine.

Study Visits:

About 4-6 weeks after completion of radiation, you will have a skin check, and a photograph will be taken of the affected area. If you are unable to make this appointment, you may submit an electronic photograph taken during this time interval or bring a photograph with you to your next follow up visit. You will also complete the symptom questionnaire.

About 10-14 weeks after completion of radiation, you will complete the symptom questionnaire again. If you are unable to come to this visit you will be asked to take pictures of the affected area(s) at home with a ruler or standard-sized object, like a penny. The questionnaire will be done over the phone, and you may be asked additional questions about the affected area(s).

After this, you will be scheduled to follow up again around 6-8 months after you finish treatment, then every 6-12 months until it has been about 2 years since you completed radiation. At these visits:

  • You will have photographs taken of the affected area(s).
  • You will complete the questionnaire about your symptoms.

Additional visits may be scheduled if the doctor thinks it is needed.

Length of Study Participation:

You will be on study for about 2 years, or as long as the study doctor thinks it is in your best interest. You will no longer be able to take part if intolerable side effects occur or if you are unable to follow study directions.

After your participation in the study has ended, the photographs taken of you may be used in future studies or in future publications. If so, every attempt will be made to edit the photographs to remove any features that could be used to identify you.

If you leave the study and the study doctor thinks it is needed, you will receive the standard dose of radiation. In that case you will sign a separate consent that explains the procedure, as well as its risks.

Interventional
Phase 2
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
  • Mycosis Fungoides
  • Malignant Neoplasms Stated as Primary Lymphoid Haematopoietic
  • Radiation: Radiation Therapy
    Radiation delivered in 1 or 2 fractions (including BID treatments to complete treatment in 1 day for patients receiving 4 Gy). Fractionation determined by the treating physician The total dose is 4 Gy.
    Other Name: XRT
  • Behavioral: Symptom Questionnaire
    Symptom questionnaire completed at baseline, 4-6 weeks after radiation, 1-14 weeks after radiation, 6-8 months after radiation, then every 6-12 months after radiation for 2 years.
    Other Name: Survey
  • Other: Photographs
    Photographs taken of the affected area(s) at baseline, at 4-6 weeks after radiation, 6-8 months after radiation, then every 6-12 months after radiation for 2 years.
  • Procedure: Microbiome Analysis
    The lesion and unaffected skin swabbed for microbiome analysis at baseline, and at 10-14 weeks after radiation,
Experimental: Low Dose Radiation Therapy

Radiation applied directly to the lesion on the skin. Radiation delivered in 1 or 2 fractions.

Symptom questionnaire completed at baseline, 4-6 weeks after radiation, 1-14 weeks after radiation, 6-8 months after radiation, then every 6-12 months after radiation for 2 years.

Photographs taken of the affected area(s) at baseline, at 4-6 weeks after radiation, 6-8 months after radiation, then every 6-12 months after radiation for 2 years.

The lesion and unaffected skin swabbed for microbiome analysis at baseline, and at 10-14 weeks after radiation,

Interventions:
  • Radiation: Radiation Therapy
  • Behavioral: Symptom Questionnaire
  • Other: Photographs
  • Procedure: Microbiome Analysis
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
50
20
September 2021
September 2020   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  1. Patients 18 years or older at presentation with pathologically confirmed MF with cutaneous involvement. *Patients must have clinically measurable disease of at least 1 lesion on physical (skin) exam. *If a patient has a prior pathological diagnosis of MF and is clinically diagnosed with a new lesion, the new lesion is eligible for enrollment without additionally biopsy confirmation.
  2. Lesions of any surface span as long as </= 1 cm in maximal height measured from the skin surface for which local control is desired are eligible; a single patient may have multiple eligible lesions that are individually enrolled for the study.
  3. All stages of disease (IA through IVB) where radiation therapy is being considered for local control are eligible. Patients who are concomitantly undergoing systemic therapy for more advanced stage disease are eligible.
  4. Patients who are concomitantly undergoing systemic therapy for more advanced stage disease are eligible.
  5. Female patients of childbearing potential must have a negative serum pregnancy test (betahCG) within 2 weeks of protocol entry if the patient is unsure of their pregnancy status. Patient signature declaring that they are not pregnant on the informed consent for treatment that is used in the Department of Radiation Oncology is also an acceptable substitution for a serum pregnancy test.
  6. Patients who are receiving or are planned to start topical chemotherapeutics, retinoids or imiquimod to other lesions that are not planned for enrollment are eligible; however, the lesion being considered for enrollment should not be under active therapy with these topical agents immediately prior to enrollment. * Use of topical chemotherapeutics, retinoids or imiquimod on the lesion that is a candidate for enrollment must be halted at least 24 hours prior to enrollment in the study.

Exclusion Criteria:

  1. Pregnant patients do not meet inclusion criteria for radiation therapy. *Patients who subsequently become pregnant may continue follow up within the protocol, but a negative urine pregnancy test will need to be obtained before additional lesions may be enrolled.
  2. Patients with active lupus or scleroderma
  3. Lesions with a height >1 cm measured from the skin surface are not eligible for this protocol.
Sexes Eligible for Study: All
18 Years and older   (Adult, Older Adult)
No
Contact: Bouthaina Dabaja, MD 713-563-2300 bdabaja@mdanderson.org
United States
 
 
NCT03398161
2017-0276
NCI-2018-00861 ( Registry Identifier: NCI CTRP )
No
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No
Not Provided
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Not Provided
Principal Investigator: Bouthaina Dabaja, MD M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
August 2018

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP